Tracking immune responses to pembrolizumab for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing whether a drug called pembrolizumab (an immunotherapy that helps your immune system fight cancer) is effective for people with advanced non-small cell lung cancer. If you haven't had treatment yet and meet the health criteria, this study could offer a new option to control your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lung cancer called non-small cell lung cancer (adenocarcinoma) that is stage IV or stage III that can't be removed with surgery.
- You must have at least one tumor that can be measured on scans.
- You must be in good enough physical condition to manage daily activities (ECOG score 0 or 1).
- Your organs (like liver, kidneys, and bone marrow) must be working well enough, based on blood tests.
- You cannot have certain genetic changes (like EGFR or ALK) that are known to drive cancer growth.
- You must not have had any prior systemic cancer treatment for this cancer, and no active brain metastasis or another cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether the immunotherapy drug pembrolizumab (Keytruda) works better for people with advanced non-small cell lung cancer by looking at their immune system's T-cells (a type of white blood cell). The goal is to understand which patients benefit most, which could help guide more personalized treatment.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial tests whether pembrolizumab alone, or pembrolizumab plus chemotherapy, can treat stage IV non-small cell lung cancer. It may help shrink tumors and improve outcomes by boosting the immune system, with or without added chemotherapy.
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
This trial tests a new combination of drugs (Keytruda with or without chemotherapy) to see if it works better for advanced lung cancer. It's for people who haven't had immunotherapy or chemotherapy for their cancer that has spread.
This trial compares pembrolizumab (an immunotherapy drug) given alone versus combined with chemotherapy for women with advanced non-small cell lung cancer that has a high level of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if adding chemotherapy improves outcomes.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.